糖尿病伴左心室射血分数保留的心衰：当前药物治疗的综述。
Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy.
机构信息
Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
出版信息
J Diabetes Res. 2022 Mar 7;2022:3366109. doi: 10.1155/2022/3366109. eCollection 2022.
Abstract
Diabetes is associated with several diabetic-related abnormalities which increase the risk of onset or worsening of heart failure. Recent studies showed that the majority of diabetic patients present with heart failure with preserved ejection fraction (HFpEF), and the prevalence of HFpEF in diabetics is alarming. Moreover, outcomes in HFpEF are poor and could be compared to those of heart failure with reduced ejection fraction (HFrEF), with 1-year mortality ranging between 10 and 30%. In contrast to HFrEF, there is very limited evidence for pharmacologic therapy in symptomatic patients with preserved ejection fraction, and therefore, the optimal selection of treatment for diabetic HFpEF remains challenging. This narrative review article summarizes the currently available data on the pharmacological treatment of HFpEF in patients with diabetes.
摘要
糖尿病与多种糖尿病相关的异常有关，这些异常会增加心力衰竭发病或恶化的风险。最近的研究表明，大多数糖尿病患者表现出射血分数保留的心力衰竭（HFpEF），而糖尿病患者中 HFpEF 的患病率令人震惊。此外，HFpEF 的预后较差，可与射血分数降低的心力衰竭（HFrEF）相媲美，1 年死亡率在 10%至 30%之间。与 HFrEF 不同，对于射血分数保留的有症状患者，药物治疗的证据非常有限，因此，糖尿病性 HFpEF 的最佳治疗选择仍然具有挑战性。本文综述了目前关于糖尿病患者 HFpEF 药物治疗的可用数据。
相似文献
1
Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy.糖尿病伴左心室射血分数保留的心衰：当前药物治疗的综述。
J Diabetes Res. 2022 Mar 7;2022:3366109. doi: 10.1155/2022/3366109. eCollection 2022.
2
In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.根据临床表现（新发与恶化）和射血分数划分的急性心力衰竭患者的院内及1年预后。来自IN-HF结局登记研究的结果
Int J Cardiol. 2014 May 1;173(2):163-9. doi: 10.1016/j.ijcard.2014.02.018. Epub 2014 Feb 22.
3
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.PARAGON-HF 试验中射血分数保留的心力衰竭患者的基线特征。
Circ Heart Fail. 2018 Jul;11(7):e004962. doi: 10.1161/CIRCHEARTFAILURE.118.004962.
4
Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.在一项为期5年的随访回顾性研究中，老年患者中射血分数保留的心力衰竭比射血分数降低的心力衰竭具有更好的长期预后。
Int J Cardiol. 2017 Apr 1;232:86-92. doi: 10.1016/j.ijcard.2017.01.048. Epub 2017 Jan 5.
5
Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.背景药理学治疗在 ANTHEM-HF 中的应用：与新型心力衰竭治疗药物的当代试验比较。
ESC Heart Fail. 2019 Oct;6(5):1052-1056. doi: 10.1002/ehf2.12484. Epub 2019 Jul 24.
6
Sex-related differences in chronic heart failure: a community-based study.性别与慢性心力衰竭相关性差异：一项基于社区的研究。
J Cardiovasc Med (Hagerstown). 2021 Jan;22(1):36-44. doi: 10.2459/JCM.0000000000001049.
7
[Pharmacological therapy of heart failure with reduced ejection fraction].射血分数降低的心力衰竭的药物治疗
Ther Umsch. 2018 Sep;75(3):180-186. doi: 10.1024/0040-5930/a000986.
8
Clinical Characteristics and Long-Term Outcomes of Patients with Acute Decompensated Heart Failure with Mid-Range Ejection Fraction.中度射血分数急性失代偿性心力衰竭患者的临床特征及长期预后
Int Heart J. 2019 Jul 27;60(4):862-869. doi: 10.1536/ihj.18-631. Epub 2019 Jun 14.
9
Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.醛固酮受体拮抗剂对射血分数保留的心力衰竭患者心功能的影响：一项随机对照试验的系统评价和荟萃分析。
Heart Fail Rev. 2019 May;24(3):367-377. doi: 10.1007/s10741-018-9758-0.
10
Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.美国一家学术医疗中心射血分数降低的心力衰竭患者的药物治疗模式、治疗结果及卫生资源利用情况
Pharmacotherapy. 2016 Feb;36(2):174-86. doi: 10.1002/phar.1701. Epub 2016 Feb 3.
引用本文的文献
1
Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials.射血分数保留的心力衰竭的药物治疗和合并症管理进展：来自临床试验的证据
Heart Fail Rev. 2024 Mar;29(2):305-320. doi: 10.1007/s10741-023-10338-x. Epub 2023 Aug 10.
本文引用的文献
1
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
2
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
3
Mineralocorticoid Receptor Antagonist Improves Cardiac Structure in Type 2 Diabetes: Data From the MIRAD Trial.醛固酮受体拮抗剂改善 2 型糖尿病患者的心脏结构：MIRAD 试验数据。
JACC Heart Fail. 2021 Aug;9(8):550-558. doi: 10.1016/j.jchf.2021.02.016.
4
Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction.左心房最小容积对射血分数保留心力衰竭的预后价值。
J Am Heart Assoc. 2021 Aug 3;10(15):e019545. doi: 10.1161/JAHA.120.019545. Epub 2021 Jul 30.
5
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.达格列净治疗射血分数保留和轻度降低的心衰：DELIVER 试验的原理和设计。
Eur J Heart Fail. 2021 Jul;23(7):1217-1225. doi: 10.1002/ejhf.2249. Epub 2021 Jun 9.
6
Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review.西班牙2型糖尿病患者心血管疾病的流行病学和经济负担：一项系统综述
Diabetes Ther. 2021 Jun;12(6):1631-1659. doi: 10.1007/s13300-021-01060-8. Epub 2021 May 3.
7
Computational Modeling Studies of the Roles of Left Ventricular Geometry, Afterload, and Muscle Contractility on Myocardial Strains in Heart Failure with Preserved Ejection Fraction.左心室几何形状、后负荷和心肌收缩力对射血分数保留心力衰竭心肌应变作用的计算模型研究。
J Cardiovasc Transl Res. 2021 Dec;14(6):1131-1145. doi: 10.1007/s12265-021-10130-y. Epub 2021 Apr 29.
8
Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.沙库巴曲缬沙坦通过抑制心室血管僵硬度抑制肥胖相关舒张功能障碍。
Cardiovasc Diabetol. 2021 Apr 21;20(1):80. doi: 10.1186/s12933-021-01270-1.
9
Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction.利拉鲁肽改善舒张期心功能主要依赖于体重减轻，但独立于体重减轻，有助于降低射血分数保留的 2 型糖尿病患者的 B 型利钠肽。
J Diabetes Res. 2021 Mar 27;2021:8838026. doi: 10.1155/2021/8838026. eCollection 2021.
10
LA reservoir strain: a sensitive parameter for estimating LV filling pressure in patients with preserved EF.左心房储器应变：评估 EF 正常患者左心房充盈压的敏感参数。
Int J Cardiovasc Imaging. 2021 Sep;37(9):2707-2716. doi: 10.1007/s10554-021-02235-x. Epub 2021 Apr 10.
Zotero 插件